Does Medicare cover Wegovy and Zepbound for weight loss? Since 1 July 2026, yes, for eligible Part D enrollees, through the Medicare GLP-1 Bridge: a $50 monthly copay, central prior authorization and a fixed end date of 31 December 2027. The Part D statute that excludes weight-loss drugs has not changed.
Here is the argument of this piece. The headlines in May and July 2026 said Medicare now covers weight-loss drugs, and for a patient at the pharmacy counter that is close enough. In law it is not Part D coverage. The Medicare GLP-1 Bridge is a time-limited demonstration that runs outside the Part D benefit, with its own processor, its own copay and its own sunset. The permanent route, the Part D side of the CMS model called BALANCE, was delayed for 2027 on 21 April 2026 with no new date. Anyone who starts Wegovy, Zepbound or Foundayo through Medicare this autumn is starting a long-term drug on a programme that, as written today, stops in 14 months.
Nothing below is medical, insurance or legal advice, and this page does not tell anyone whether to take a GLP-1. It reports what CMS, the statute and published analyses say, with each document linked. The criteria quoted come from the CMS prescriber fact sheet dated June 2026, and eligibility is decided by CMS through the prescriber's prior authorization, not by any website. For the approval status of semaglutide, tirzepatide and the peptides around them, the Ozemback status tracker keeps a dated row per compound, and our piece on the orforglipron approval timeline covers the pill now sold as Foundayo.
Why didn't Medicare cover weight-loss drugs before 2026?
The Part D statute excludes them. Part D defines a covered drug in 42 U.S.C. 1395w-102(e), and paragraph (e)(2)(A) removes any drug or medical use that state Medicaid programmes may exclude under 42 U.S.C. 1396r-8(d)(2), with carve-outs for smoking cessation and a few other classes. The first item on that Medicaid list reads "agents when used for anorexia, weight loss, or weight gain". The result is that a Part D plan can cover semaglutide as Ozempic for type 2 diabetes, or Wegovy for cardiovascular risk reduction, but not the same molecule prescribed only to reduce weight. KFF's brief of 11 May 2026 describes Medicare as "prohibited by law" from covering drugs used specifically for weight loss, and nothing enacted in 2026 amended that text.
The Bridge gets around the exclusion by changing the channel, not the law. Section 402 of the Social Security Amendments of 1967 lets CMS run payment demonstrations, and the CMS memo of 21 April 2026 calls the Bridge "a time-limited Section 402 demonstration" that gives eligible Part D beneficiaries certain GLP-1 drugs "outside of the Medicare Part D benefit coverage and payment flow". Part D plans do not pay, the plan formulary is not involved, and the drug never becomes a covered Part D drug. That design explains why the copay, the paperwork and the end date look different from everything else a Medicare patient fills at the same pharmacy, and why the exclusion in the statute still stands untouched.
What is the Medicare GLP-1 Bridge and what does it cost?
The Medicare GLP-1 Bridge is a CMS demonstration that started on 1 July 2026 and, after the extension announced on 21 April 2026, runs to 31 December 2027. The CMS programme page sets a $50 copay for eligible beneficiaries and adds three conditions that matter at the counter: the Part D deductible does not apply, no low-income subsidy is provided, and "no part of the $50 copay counts towards" true out-of-pocket costs, the running total that triggers the Part D annual cap. A single central processor handles prior authorization, claims and pharmacy payment. KFF reports that manufacturers agreed a net price of $245 per 30-day supply, with CMS paying pharmacies close to list price and the manufacturer owing the difference, and that CMS has not disclosed a projected cost.
| Product | Under the Bridge | Source |
|---|---|---|
| Wegovy injection | Covered | CMS prescriber fact sheet, June 2026 |
| Wegovy tablets | Covered | CMS prescriber fact sheet, June 2026 |
| Zepbound KwikPen | Covered | CMS prescriber fact sheet, June 2026 |
| Foundayo tablets (orforglipron) | Covered | CMS prescriber fact sheet, June 2026 |
| Zepbound single-dose pen | Not covered | CMS prescriber fact sheet, June 2026 |
| Zepbound vials | Not covered | CMS prescriber fact sheet, June 2026 |
| Ozempic, Mounjaro | Not listed; diabetes use goes through the Part D plan | CMS prescriber fact sheet, June 2026 |
The vial exclusion is the detail most coverage stories skipped. Lilly's direct cash-pay channel, which our LillyDirect analysis followed, has sold Zepbound in single-dose vials, and the CMS prescriber fact sheet states that single-dose pens and vials are not covered. A Medicare patient already paying cash for vials therefore has to change device to use the Bridge. Only 28-day or 30-day fills are covered, so there is no 90-day supply, and any switch between covered drugs, for example from Wegovy injection to Foundayo tablets, needs a new prior authorization. Foundayo is orforglipron, the Lilly pill the FDA approved for adults with obesity on 1 April 2026, which makes it the newest product on the list.
Medicare did not change the law that bans weight-loss drugs from Part D. It built a $50 side door next to it, and the side door has a closing date.
Who qualifies for Medicare coverage of Wegovy or Zepbound?
Eligibility runs through two filters. The first is the plan and the diagnosis. CMS says most people with Part D coverage can qualify, but not those in private fee-for-service plans, cost contract plans, PACE organisations and several other plan types unless they also hold a standalone drug plan. Anyone who has already received a GLP-1 through their Part D plan is out, and so is anyone with type 2 diabetes, moderate-to-severe sleep apnea or MASH, the liver disease once called NASH. For those patients CMS sends the request to the Part D plan instead. The second filter is clinical and is set by body mass index at the start of treatment, with three tiers that the fact sheet lists in full.
| BMI at start of therapy | Also required |
|---|---|
| 35 or more | Nothing else |
| 30 or more | Heart failure with preserved ejection fraction, uncontrolled hypertension (above 140/90 despite two medicines), or chronic kidney disease stage 3a or above |
| 27 or more | Prediabetes, previous heart attack, previous stroke, or symptomatic peripheral artery disease |
Two details in that table change who gets in. The BMI that counts is the one recorded "at the time my patient starts GLP-1 therapy", in the wording of the prescriber attestation, so a person who began Wegovy on cash and has since lost weight is judged on the starting figure, not on today's. And the prescriber signs the prior authorization under penalty of perjury; the CMS fact sheet warns that the programme may verify answers, such as the absence of type 2 diabetes, against Medicare data. A decision reaches the patient by mail and the prescriber within 72 hours of submission, and a denial believed to be wrong can be resubmitted. Later fills need no new authorization unless the drug changes.
What happens to Medicare GLP-1 coverage after 2027?
CMS has not published the answer. The original plan was BALANCE, the Better Approaches to Lifestyle and Nutrition for Comprehensive Health model, which was meant to bring negotiated GLP-1 prices into Part D plans from 2027 and into state Medicaid programmes from 2026. On 21 April 2026 CMS told Part D sponsors it would "delay implementation of the Medicare Part D portion" for calendar year 2027 "pending further evaluation and data collection", and told them not to indicate participation in their 2027 bids. The memo frames the extended Bridge as the source of the utilization data plans asked for, and promises only further information. As of 1 November 2026 we found no CMS notice giving a Part D start date for BALANCE.
The Medicaid half of BALANCE kept moving. The same CMS memo says states could apply until 31 July 2026 and start on a date of their choosing between 1 May 2026 and 1 January 2027, after which entry is at CMS discretion. KFF counted 13 state Medicaid programmes covering GLP-1s for obesity in January 2026, down from 16 in 2025, a decline our state-by-state coverage report tracked as it happened. For people who hold both Medicare and Medicaid, Medicare is the drug payer, so the Bridge rules apply to them too, including the line on the CMS page that no low-income subsidy is provided against the $50 copay.
Is the Bridge real coverage or only a pilot?
The strongest case against this reading is that the label matters less than the result. A beneficiary who qualifies pays $50 a month for a brand-name GLP-1, gets a decision within 72 hours, and does not have to enrol in anything separately; the pharmacy routes the claim. CMS also extended the Bridge once rather than letting it lapse after six months, and the reason it gave in April was to prepare Part D plans for BALANCE, not to wind the programme down. On that view, calling the Bridge temporary is pedantry. Switching off $50 GLP-1s for older adults who are already taking them would carry a political cost that no administration would want to pay, whatever the statute says.
The reply is that the risk sits with the patient, not with the programme. Weight regain after stopping a GLP-1 is one of the most consistent findings in this class, as our reading of the STEP-4 withdrawal trial sets out, which is why a fixed end date matters more here than in most pilots. The statute still excludes weight-loss drugs from Part D, the Part D route has no date, and the $50 does not count toward the out-of-pocket cap, so a patient who also takes expensive drugs gets no help reaching it. Anyone starting now is relying on a second extension or on BALANCE reaching Part D by January 2028, and neither has been promised in writing by CMS.
What should a Medicare patient check before using the Bridge?
The checks are administrative, not clinical. The plan has to be Part D coverage, or come with a standalone drug plan. The prescription has to name a covered product, which rules out Zepbound vials and single-dose pens, and, according to the CMS prescriber sheet, carry an E66 obesity diagnosis code with the note "SEND TO BRIDGE FOR WEIGHT MANAGEMENT"; without it the pharmacy may send the claim to the Part D plan and get a rejection. The date to keep in view is 31 December 2027. Ozemback's view is that the Bridge is real access built on a temporary legal base, and that the story of 2027 is whether CMS turns it into Part D coverage or lets the exclusion written into Part D in 2003 win by default. We will report it the day CMS publishes, and the newsletter is the fastest way to get that update.
Sources
- Centers for Medicare & Medicaid Services, Medicare GLP-1 Bridge, programme page, last updated 13 July 2026. www.cms.gov
- CMS, Medicare GLP-1 Bridge: information for prescribers, CMS Product No. 12235, June 2026. www.cms.gov
- CMS, Medicare GLP-1 Bridge: information for providers. www.cms.gov
- CMS, HPMS memo, Status update on the Bridge demo and BALANCE Model in Part D for CY2027, 21 April 2026. www.cms.gov
- KFF, What to know about the BALANCE Model for GLP-1s in Medicare and Medicaid and the Medicare GLP-1 Bridge, 11 May 2026. www.kff.org
- 42 U.S.C. 1395w-102(e), Part D covered drug definition and exclusions, Cornell Legal Information Institute. www.law.cornell.edu
- 42 U.S.C. 1396r-8(d)(2), drugs that may be excluded or restricted, Cornell Legal Information Institute. www.law.cornell.edu
- Healio, FDA approves orforglipron, an oral GLP-1 for adults with obesity, 1 April 2026. www.healio.com
